Frank Yocca - BioXcel Therapeutics Chief Scientific Officer
| BTAI Stock | USD 0.36 0.02 5.88% |
Executive
Dr. Frank D. Yocca, Ph.D. is Chief Scientific Officer of the Company. From April 2015 to April 2017, he was Senior Vice President, CNS RD of BioXcel. From 2005 to 2015, Dr. Yocca held multiple leadership roles at AstraZeneca plc, including Vice President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit, Vice President and Head, Strategy Unit, CNS and Pain Innovative Medicine Unit and Vice President and Head, CNS Pain Discovery . Prior to this he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this Dr. Yocca served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer clinical candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of the Early and Late Discovery and Development Teams from 1984 to 2001 since 2017.
| Age | 69 |
| Tenure | 8 years |
| Address | 555 Long Wharf Drive, New Haven, CT, United States, 06511 |
| Phone | 475 238 6837 |
| Web | https://www.bioxceltherapeutics.com |
Frank Yocca Latest Insider Activity
Tracking and analyzing the buying and selling activities of Frank Yocca against BioXcel Therapeutics stock is an integral part of due diligence when investing in BioXcel Therapeutics. Frank Yocca insider activity provides valuable insight into whether BioXcel Therapeutics is net buyers or sellers over its current business cycle. Note, BioXcel Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioXcel Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Frank Yocca over a month ago Disposition of 225 shares by Frank Yocca of BioXcel Therapeutics at 0.3512 subject to Rule 16b-3 | ||
Frank Yocca over a month ago Disposition of 562 shares by Frank Yocca of BioXcel Therapeutics subject to Rule 16b-3 | ||
Frank Yocca over a month ago Disposition of 521 shares by Frank Yocca of BioXcel Therapeutics subject to Rule 16b-3 | ||
Frank Yocca over three months ago Disposition of 521 shares by Frank Yocca of BioXcel Therapeutics subject to Rule 16b-3 |
BioXcel Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6362) % which means that it has lost $0.6362 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Return On Equity is estimated to increase to 3.83, while Return On Tangible Assets are projected to decrease to (2.30). As of now, BioXcel Therapeutics' Non Current Assets Total are increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.30, while Non Currrent Assets Other are projected to decrease to under 95 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Candice Masse | Elevation Oncology | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 58 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Thomas Hare | Madrigal Pharmaceuticals | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 60 | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 49 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 54 | |
| Dana Aftab | Exelixis | 61 | |
| Geoffrey Barker | Viking Therapeutics | N/A | |
| CPA CPA | Viking Therapeutics | 54 | |
| JD Esq | Apellis Pharmaceuticals | 52 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Robert Yang | Elevation Oncology | N/A | |
Management Performance
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.64 |
BioXcel Therapeutics Leadership Team
Elected by the shareholders, the BioXcel Therapeutics' board of directors comprises two types of representatives: BioXcel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioXcel. The board's role is to monitor BioXcel Therapeutics' management team and ensure that shareholders' interests are well served. BioXcel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioXcel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Yocca, Chief Scientific Officer | ||
| Richard MBA, Senior CFO | ||
| Mary Coleman, VP Relations | ||
| Javier Rodriguez, Chief VP | ||
| Cedric Burg, VP Management | ||
| Robert Scala, Vice Planning | ||
| Chetan Lathia, Clinical Medicine | ||
| Robert MD, Chief Neuroscience | ||
| Krishnan Nandabalan, Chief Director | ||
| Vimal Mehta, President CEO, Secretary, Director | ||
| Matthew Wiley, Senior Officer | ||
| Iris Francesconi, Market Marketing | ||
| MD BSc, VP Officer | ||
| BSc MD, Chief VP | ||
| Friso Postma, Senior intelligence |
BioXcel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioXcel Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.67 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (14.89) % | ||||
| Current Valuation | 81.65 M | ||||
| Shares Outstanding | 49.63 M | ||||
| Shares Owned By Insiders | 20.06 % | ||||
| Shares Owned By Institutions | 8.70 % | ||||
| Number Of Shares Shorted | 807.68 K | ||||
| Price To Earning | (2.62) X | ||||
| Price To Book | 3.97 X |
Currently Active Assets on Macroaxis
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share | Quarterly Revenue Growth 1.416 | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.